U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula CO3.Cu
Molecular Weight 123.555
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CUPRIC CARBONATE

SMILES

[Cu++].[O-]C([O-])=O

InChI

InChIKey=GEZOTWYUIKXWOA-UHFFFAOYSA-L
InChI=1S/CH2O3.Cu/c2-1(3)4;/h(H2,2,3,4);/q;+2/p-2

HIDE SMILES / InChI

Molecular Formula Cu
Molecular Weight 63.546
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula CO3
Molecular Weight 60.0089
Charge -2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a84d61a4-8e7f-4be1-aba6-f633b334aafc | http://www.sciencedirect.com/science/article/pii/S0167488912000158https://www.ncbi.nlm.nih.gov/pubmed/16971307DOI: 10.1107/s0567740869001725 Retrived from http://scripts.iucr.org/cgi-bin/paper?S0567740869001725https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=522.518 | http://www.worldofchemicals.com/chemicals/chemical-properties/cupric-glycinate.htmlhttps://www.ncbi.nlm.nih.gov/pubmed/8556785 | https://www.ncbi.nlm.nih.gov/pubmed/2135524https://www.ncbi.nlm.nih.gov/pubmed/15704330 | https://www.ncbi.nlm.nih.gov/pubmed/12425037 | https://www.ncbi.nlm.nih.gov/pubmed/1599240 | http://www.certisusa.com/pdf-labels/Kocide3000_label.pdf | http://www.pesticideinfo.org/Detail_Chemical.jsp?Rec_Id=PC33524http://www.emdmillipore.com/US/en/product/Copper-di-ammonium-Titriplex-solution,MDA_CHEM-105217http://www.drugfuture.com/chemdata/tetraamminecopper-sulfate.html | https://cameochemicals.noaa.gov/chemical/3026https://www3.epa.gov/pesticides/chem_search/ppls/019713-00509-20110705.pdfhttp://fs1.agrian.com/pdfs/CORE_7.5_Copper_EDTA_Label.pdfhttps://www.ncbi.nlm.nih.gov/pubmed/6526221http://www.ema.europa.eu/docs/en_GB/document_library/Maximum_Residue_Limits_-_Report/2009/11/WC500013010.pdfhttps://www.ncbi.nlm.nih.gov/pubmed/24106015 | https://www.ncbi.nlm.nih.gov/pubmed/20942456http://www.drugfuture.com/chemdata/schweizer-s-reagent.html | http://pubs.acs.org/doi/abs/10.1021/ed062p878?journalCode=jceda8 | http://pubs.acs.org/doi/abs/10.1021/ed019p356
Curator's Comment: description was created based on several sources, including https://www.copper.org/resources/properties/compounds/other_compounds.html | http://www.vitamins-supplements.org/dietary-minerals/copper.php | https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=bea888b4-9cc6-49da-89e6-5c273b974ed1

Tetraamminecopper dihydroxide also known as Schweizer's Reagent dissolves cellulose; used in rayon production.

CNS Activity

Curator's Comment: Known to be CNS active in zebrafish. Human data not available.

Originator

Sources: http://pubs.acs.org/doi/abs/10.1021/ja01512a012Schweizer, J. Prakt. Chem. 72, 109, 344 (1857).
Curator's Comment: http://www.drugfuture.com/chemdata/schweizer-s-reagent.html

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
Unknown

Approved Use

Unknown
Preventing
Unknown

Approved Use

Unknown
Preventing
Cupric glycinate

Approved Use

Indications for use. For beef calves and beef cattle for the prevention of copper deficiency, or when labeled for veterinary prescription use, for the prevention and/or treatment of copper deficiency alone or in association with molybdenum toxicity.
Primary
COPPER•MAX

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Preventing
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Diagnostic
Unknown

Approved Use

Unknown
Preventing
COPPER

Approved Use

Copper 0.4 mg/mL (Cupric Chloride Injection, USP) is indicated for use as a supplement to intravenous solutions given for total parenteral nutrition (TPN). Administration helps to maintain copper serum levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms.
Preventing
COPINOX

Approved Use

Copinox 4g is indicated for the prevention and treatment of copper deficiency in cattle and sheep.
PubMed

PubMed

TitleDatePubMed
Copper Fluoride Luminescence during UV Photofragmentation of Bis(1,1,1,5,5,5-hexafluoro-2,4-pentanedionato)copper(II) in the Gas Phase.
1996 Aug 14
Cardiopulmonary events during hemodialysis: effects of dialysis membranes and dialysate buffers.
2000 Jul
The effectiveness of ecologically acceptable ways of protection of field-grown tomato (Lycopersicon lycopersicum (L.) Karsten) from tomato late blight (Phytophthora infestans (Mont.) de Bary) in extreme weather conditions.
2001
Direct catalytic aldol-type reactions using RCH2CN.
2003 Aug 21
Copper(II) acetate-catalyzed addition of arylboronic acids to aromatic aldehydes.
2009 Jan 16
Generation of oxidant response to copper and iron nanoparticles and salts: Stimulation by ascorbate.
2009 Oct 30
Copper-promoted coupling of vinyl boronates and alcohols: a mild synthesis of allyl vinyl ethers.
2010 Feb 3
Copper sulfide nanoparticles for photothermal ablation of tumor cells.
2010 Oct
Anti-ovulatory activity of H2 receptor blockers in albino rabbits--a preliminary study.
2011 Apr
Expeditious synthesis of phenanthrenes via CuBr2-catalyzed coupling of terminal alkynes and N-tosylhydrazones derived from o-formyl biphenyls.
2011 Oct 7
Zeta potential and solubility to toxic ions as mechanisms of lung inflammation caused by metal/metal oxide nanoparticles.
2012 Apr
Design, synthesis, antioxidant, and anti-breast cancer activities of novel diethyl(alkyl/aryl/heteroarylamino)(4-(pyridin-2-yl)phenyl)methylphosphonates.
2013 May
Molecular responses of mouse macrophages to copper and copper oxide nanoparticles inferred from proteomic analyses.
2013 Nov
Cytotoxicity in the age of nano: the role of fourth period transition metal oxide nanoparticle physicochemical properties.
2013 Nov 25
The modality of cell-particle interactions drives the toxicity of nanosized CuO and TiO₂ in human alveolar epithelial cells.
2013 Oct 24
Interference of CuO nanoparticles with metal homeostasis in hepatocytes under sub-toxic conditions.
2014
Synthesis and biomedical applications of copper sulfide nanoparticles: from sensors to theranostics.
2014 Feb 26
Effects of different sources of copper on Ctr1, ATP7A, ATP7B, MT and DMT1 protein and gene expression in Caco-2 cells.
2014 Jul
Electron induced surface reactions of organometallic metal(hfac)₂ precursors and deposit purification.
2014 Jun 11
A Facile Strategy for Catalyst Separation and Recycling Suitable for ATRP of Hydrophilic Monomers Using a Macroligand.
2016 Jan
Unusual 4-arsonoanilinium cationic species in the hydrochloride salt of (4-aminophenyl)arsonic acid and formed in the reaction of the acid with copper(II) sulfate, copper(II) chloride and cadmium chloride.
2017 Apr 1
Roles of Copper-Binding Proteins in Breast Cancer.
2017 Apr 20
Amino acid-mediated 'turn-off/turn-on' nanozyme activity of gold nanoclusters for sensitive and selective detection of copper ions and histidine.
2017 Jun 15
Patents

Sample Use Guides

In Vivo Use Guide
Copper 0.4 mg/mL (Cupric Chloride Injection) contains 0.4 mg copper/mL and is administered intravenously only after dilution. The additive should be diluted in a volume of fluid not less than 100 mL. For the adult receiving total parenteral nutrition, the suggested additive dosage is 0.5 to 1.5 mg copper/day (1.25 to 3.75 mL/day). For pediatric patients, the suggested additive dosage is 20 mcg copper/kg/day (0.05 mL/kg/day). Infants weighing less than 1500 gm may have increased requirements because of their low body reserves and increased requirements for growth.
Route of Administration: Intravenous
Human Endometrial Stromal Cells were treated with non-toxic concentrations of copper ions (0-250 uM). mRNA expressions of insulin-like growth factor binding protein (IGFBP-1), prolactin (PRL), Mn-SOD, and FOXO1 were down-regulated during decidualization following the treatments with 100 or 250 uM copper ions. Meanwhile, the amount of malonaldehyde in the supernatant of cells was increased.
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:57:53 GMT 2023
Edited
by admin
on Fri Dec 15 16:57:53 GMT 2023
Record UNII
9AOA5F11GJ
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CUPRIC CARBONATE
Common Name English
CUPROMAAG
Brand Name English
COPPER MONOCARBONATE
Systematic Name English
COPPER CARBONATE (1:1)
Systematic Name English
CARBONIC ACID, COPPER SALT
Common Name English
COPPER(II) CARBONATE
HSDB  
Systematic Name English
CARBONIC ACID, COPPER(2+) SALT (1:1)
Common Name English
COPPER (AS CARBONATE)
Common Name English
COPPER(II) CARBONATE [HSDB]
Common Name English
COPPER CARBONATE
Systematic Name English
Code System Code Type Description
PUBCHEM
14452
Created by admin on Fri Dec 15 16:57:53 GMT 2023 , Edited by admin on Fri Dec 15 16:57:53 GMT 2023
PRIMARY
FDA UNII
9AOA5F11GJ
Created by admin on Fri Dec 15 16:57:53 GMT 2023 , Edited by admin on Fri Dec 15 16:57:53 GMT 2023
PRIMARY
ECHA (EC/EINECS)
214-671-4
Created by admin on Fri Dec 15 16:57:53 GMT 2023 , Edited by admin on Fri Dec 15 16:57:53 GMT 2023
PRIMARY
WIKIPEDIA
COPPER(II) CARBONATE
Created by admin on Fri Dec 15 16:57:53 GMT 2023 , Edited by admin on Fri Dec 15 16:57:53 GMT 2023
PRIMARY
CAS
7492-68-4
Created by admin on Fri Dec 15 16:57:53 GMT 2023 , Edited by admin on Fri Dec 15 16:57:53 GMT 2023
NON-SPECIFIC STOICHIOMETRY
SMS_ID
100000156471
Created by admin on Fri Dec 15 16:57:53 GMT 2023 , Edited by admin on Fri Dec 15 16:57:53 GMT 2023
PRIMARY
CAS
1184-64-1
Created by admin on Fri Dec 15 16:57:53 GMT 2023 , Edited by admin on Fri Dec 15 16:57:53 GMT 2023
PRIMARY
HSDB
258
Created by admin on Fri Dec 15 16:57:53 GMT 2023 , Edited by admin on Fri Dec 15 16:57:53 GMT 2023
PRIMARY
EPA CompTox
DTXSID6034471
Created by admin on Fri Dec 15 16:57:53 GMT 2023 , Edited by admin on Fri Dec 15 16:57:53 GMT 2023
PRIMARY
DAILYMED
9AOA5F11GJ
Created by admin on Fri Dec 15 16:57:53 GMT 2023 , Edited by admin on Fri Dec 15 16:57:53 GMT 2023
PRIMARY
RXCUI
1427055
Created by admin on Fri Dec 15 16:57:53 GMT 2023 , Edited by admin on Fri Dec 15 16:57:53 GMT 2023
PRIMARY RxNorm
EVMPD
SUB130387
Created by admin on Fri Dec 15 16:57:53 GMT 2023 , Edited by admin on Fri Dec 15 16:57:53 GMT 2023
PRIMARY
MESH
C086270
Created by admin on Fri Dec 15 16:57:53 GMT 2023 , Edited by admin on Fri Dec 15 16:57:53 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY